Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Inclusion Criteria:

• Age ≥18 years

• Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment withTTFields with or without systemic therapy, confirmed by the enrolling institution

• Able to self-administer topical interventions or has available another person whocan apply the topical agents

• Treatment with TTF should be initiated within 7 days of planned initiation on thistrial.

Exclusion Criteria:

• Known history of allergy to any ingredient of the study agents

• Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion ofthe investigator, will affect the grading of skin adverse events, confirmed byenrolling institution.

• Use of concurrent topical therapy to the scalp for another dermatologic condition

• Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment

• Use of greater than 4 mg dexamethasone a day within 14 days of enrollment

• Malignant glioma

• Pregnant Women